Abstracts

1283 – Topical Doxycycline Inserts Show High Efficacy Against Vaginal Chlamydia Acquisition in Macaques

Background Bacterial STIs are on the rise globally. Fast-dissolving dual-compartment (vaginal/rectal) inserts containing doxycycline (DOX) provide an alternate approach to STI prevention that can maximize local DOX concentrations while minimizing systemic distribution.   Here, we performed preclinical studies to evaluate the pharmacokinetics (PK) and protective efficacy following vaginal administration of CONRAD-developed inserts containing DOX against vaginal C.…

1276 – Doxycycline Post-Exposure Prophylaxis Continuum of Care Among MSM in Philadelphia, 2023

Background Doxycycline post-exposure prophylaxis (Doxy-PEP) is an effective tool for reducing bacterial sexually transmitted infection (STI) incidence among men who have sex with men (MSM). We sought to understand current rates of bacterial STIs (gonorrhea, chlamydia, syphilis) among MSM and generate Philadelphia’s first doxy-PEP continuum among MSM. Methods We used 2023 National HIV Behavioral Surveillance…

1281 – Increased Knowledge and Use of Doxycycline Postexposure Prophylaxis in King County, Washington

Background Following evidence of doxycycline postexposure prophylaxis (doxyPEP) efficacy to prevent chlamydia, gonorrhea and syphilis among men and transgender women who have sex with men, Public Health – Seattle & King County (PHSKC) released provider guidance in June 2023. We utilized data from PHSKC’s annual Pride Survey to assess changes in knowledge and self-reported doxyPEP…

1260 – Physical, Psychosocial, and Sexual Health in Adults Aged 50+ With and Without HIV in Denmark

Background With age, people with HIV (PWH) may face higher rates of physical comorbidities, psychosocial challenges and sexual health problems, all of which can impact quality of life and ART adherence. However, research on health among ageing PWH remains limited. This study aimed to examine self-reported physical, psychosocial and sexual health outcomes among people aged…

1285 – Antimicrobial Resistance of N. gonorrhoeae at a Community-Based Clinic, 2023-2024

Background Gonorrhea, caused by N. gonorrhoeae, has developed resistance to most antimicrobial treatments over time, including ciprofloxacin, tetracycline, penicillin, and cephalosporins. Importantly, baseline tetracycline resistance may impact the use of doxycycline as post-exposure prophylaxis (DoxyPEP) to prevent bacterial STIs. We evaluated baseline N. gonorrhoeae resistance in patients presenting to a community-based STI clinic. Methods We…

1247 – Has Rapid Scale-Up of Dual HIV/Syphilis Testing in Antenatal Care Improved Syphilis Testing Coverage?

Background In 2022 there were approximately 130,000 child HIV infections and 700,000 cases of congenital syphilis globally. Through concerted effort substantial progress has been made in both HIV and syphilis testing coverage to identify infections in pregnancy and to offer treatment. However, gaps remain, including the gap between HIV and syphilis testing. Dual HIV/syphilis rapid…

1262 – Incidence and Clearance of Anal Human Papillomavirus Infection in an Acute HIV Cohort in Thailand

Background Anal high-risk human papillomavirus (HRHPV) infection, especially human papillomavirus (HPV) 16, is the leading cause of anal cancer. This study explored factors associated with HRHPV incidence and clearance among individuals with acute HIV acquisition. Methods Participants who initiated antiretroviral therapy during acute HIV acquisition, defined as Fiebig stages 1–5, and agreed to undergo anal…